<DOC>
	<DOCNO>NCT02768662</DOCNO>
	<brief_summary>This open-label extension study single intratympanic injection OTO-104 give every 3 month total 2 injection . Subjects must complete either Otonomy study 104-201403 ( 1-Year , Phase 2 , Safety Study OTO-104 ) 104-201508 ( Phase 3 Study OTO-104 ) order eligible open-label extension study .</brief_summary>
	<brief_title>A 6-Month Extension Study OTO-104 Meniere 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Meniere Disease</mesh_term>
	<criteria>Inclusion Criteria include , limited : Subject complete Phase 2 OTO104 1Year Safety Study ( 104201403 ) Phase 3 ( 104201508 ) clinical study . Subject diagnosis definite unilateral Meniere 's disease 1995 AAOHNS criterion Exclusion Criteria include , limited : Subject pregnant lactating . Subject history immunodeficiency disease . Subject experience adverse reaction intratympanic injection steroid .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>